Diabetic foot ulcer is the most common reason patients get HBOT in the US. It is FDA-approved, Medicare-covered, and tied to a real clinical problem: limb loss in people with diabetes.
The evidence base is larger than for any other FDA-recognized HBOT use. It is also more contested. Big trials have reached different findings.
This page lays out what the major trials show, why they disagree, and how Medicare rules shape practice.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (Wagner Grade 3 or higher) |
| UHMS classification | Tier 1 — approved adjunct to standard wound care |
| Typical protocol | 2.0-2.5 ATA, 90 min, 5 days/week, 30-40 total sessions |
| Medicare coverage | Yes — NCD 20.29, 2017 (30-day failure rule) |
| Insurance prior auth | Yes — required almost everywhere |
| Evidence grade | GRADE B-C (positive small trials, neutral cohort studies) |
The evidence
Diabetic foot ulcer is the only HBOT indication with a deep RCT literature spanning three decades. The signal is mixed.
The Faglia 1996 Diabetes Care RCT, PMID 8941460 randomized 70 hospitalized patients with severe ischemic diabetic foot ulcers. HBOT cut major amputation rates from 33 percent to 9 percent. This was the foundational positive trial.
The Margolis 2013 Diabetes Care cohort study, PMID 23423696 analyzed 6,259 Medicare patients propensity-matched for HBOT versus standard care. HBOT did not lower amputation rates or improve healing. The authors concluded HBOT was not effective in real-world Medicare practice.
The Kranke 2015 Cochrane review, PMID 26106870 pooled 12 trials on chronic wounds, with most data on diabetic foot ulcers. HBOT improved healing at six weeks but the effect did not last at one year. The review flagged trial quality concerns.
A 2021 systematic review and meta-analysis in Scientific Reports pooled controlled trials and found a roughly two-fold increase in complete wound healing with HBOT. Heterogeneity was high.
A 2024 PMC review of HBOT for diabetic foot ulcers and 2024 meta-analysis on Wagner grading, PMC both suggest that the benefit concentrates in Wagner Grade 3 and 4 ulcers with adequate arterial perfusion.
The pattern: small picked trials show benefit. Big real-world cohorts show smaller or no effect. Patient selection seems to drive the gap.
Mechanism of action
A diabetic foot ulcer is a wound that won't close in tissue with too little oxygen. The drivers are small-vessel disease, nerve damage, and weakened immune response.
Hyperbaric oxygen helps by raising plasma oxygen high enough to push it into starved wound tissue. At 2.0 to 2.5 ATA, plasma oxygen rises to about 1,500 mmHg from a baseline of 100.
The high oxygen pressure does several things. It speeds neutrophil killing of bacteria and drives fibroblast collagen synthesis. It also stimulates angiogenesis — new blood vessel growth — over a 20 to 40 session course.
The mechanism is well-mapped. The clinical question is whether the mechanism produces enough healing margin over standard wound care to justify the cost and time.
Typical protocol
The standard protocol is 2.0 to 2.5 ATA for 90 minutes. Sessions are given five days per week. Total courses run 30 to 40 sessions over six to eight weeks.
Most US centers use 2.0 ATA. Some use 2.4 ATA. The difference matters little for healing rates but affects oxygen toxicity risk.
Sessions include air breaks at higher pressures to limit CNS oxygen toxicity. Pre-session checks include ear pressure equalization training and current blood sugar status.
Patients continue standard wound care between sessions. HBOT is an adjunct, not a replacement for offloading, debridement, infection control, and glycemic management.
Insurance and cost
Medicare covers HBOT for Wagner Grade 3 or higher diabetic foot ulcer under NCD 20.29, 2017 update. The coverage rule has three legs.
First, the patient must have Type 1 or Type 2 diabetes. Second, the wound must be classified as Wagner Grade 3 or higher (osteomyelitis, abscess, or tendon involvement). Third, the wound must show no measurable healing after 30 days of standard wound care.
The 30-day rule matters. Medicare denies HBOT claims where the 30-day standard-care trial is not documented. Most regional Medicare contractors require photographs and measurements.
Cost per session ranges $300 to $1,000. A full 40-session course runs $12,000 to $40,000. Medicare's allowed amount is at the low end of that range.
Commercial insurance generally follows the Medicare framework but with stricter prior authorization. Many plans require third-party utilization review.
Where to get it
DFU HBOT is mostly given at hospital wound care centers. These centers usually have a team — wound nurse, podiatrist, hyperbaric doctor, and ID specialist.
The UHMS accredited facility directory, current 2026 is the right starting point. Most accredited facilities are hospital wound care programs.
For chamber details, see our FDA-cleared chambers list. DFU treatment can be done in monoplace or multiplace chambers. Both are FDA-cleared at 2.0 to 2.5 ATA.
Independent wellness clinics generally do not treat Wagner Grade 3 diabetic foot ulcers. The reasons are billing rules, wound care complexity, and infection control.
Limitations and contraindications
The absolute contraindication is untreated pneumothorax. Patients with severe COPD, especially with bullae, need pulmonary clearance before chamber use.
Severe ischemia is a relative limit. If foot blood flow is too low (toe pressure under 30 mmHg, ABI under 0.4), HBOT alone may not be enough. Vascular surgery to restore flow should come first.
Active untreated infection in the wound is another limit. HBOT is an adjunct to infection care, not a fix. Osteomyelitis needs targeted antibiotics and often surgical cleanup.
Glucose control matters during sessions. Severe low blood sugar in a chamber is hard to treat. Most centers check fingersticks before each session and adjust insulin timing.
The hardest real-world limit is patient adherence. A 30 to 40 session course over six to eight weeks is a major time ask. Adherence is the strongest single driver of healing in the Medicare data.
Active research
ClinicalTrials registry studies, current 2026 include several phase 3 trials on HBOT protocols, patient selection, and biomarkers.
A systematic review on Wagner-based selection in Journal of Vascular Surgery, 2019 found that benefit concentrates in patients with arterial insufficiency and Wagner Grade 3 or higher disease.
Active research questions include whether transcutaneous oxygen measurement can identify responders, whether shorter session counts (20 to 25) match longer courses, and how HBOT interacts with bioengineered skin grafts.
How this compares to off-label HBOT uses
Diabetic foot ulcer is FDA-approved, Medicare-covered, and supported by a deep but mixed trial literature. It is also the most common HBOT use in the US and the highest Medicare-reimbursed indication.
This is fundamentally different from off-label HBOT for things like brain injury, long COVID, or anti-aging. Those uses are not FDA-approved, not Medicare-covered, and do not have a Faglia-equivalent foundational RCT showing major amputation reduction.
For context on how off-label HBOT marketing diverges from clinical evidence, read our analysis of institutional silence on HBOT and our breakdown of marketing-driven HBOT claims.
DFU HBOT is medicine, not wellness. The treatment is given in hospital wound care centers under Medicare rules with a defined patient group. That is the line.
Frequently asked questions
How much healing benefit does HBOT actually add?
Small selective trials show two-fold or greater improvement in complete healing. Large real-world Medicare cohorts show smaller or no benefit. The truth likely lies in between, and patient selection matters a lot.
Why does Medicare require 30 days of standard care first?
Most ulcers heal with debridement, offloading, infection control, and glucose management alone. The 30-day rule identifies wounds that have not healed despite the basics. Those are the wounds with the best HBOT case.
Is HBOT a substitute for surgical revascularization?
No. If foot arterial perfusion is too low, HBOT cannot deliver enough oxygen even at 2.5 ATA. Vascular surgery to restore blood flow comes first in those patients.
How do I know if my wound is Wagner Grade 3?
A Wagner Grade 3 ulcer involves deep tissue with abscess, osteomyelitis, plantar space infection, or tendon involvement. The grading requires hands-on assessment by a wound specialist. Grade 1 and 2 ulcers are not Medicare-covered for HBOT.
Can a soft-shell wellness chamber treat a diabetic foot ulcer?
No. DFU treatment requires 2.0 to 2.5 ATA. Soft-shell chambers do not reach those pressures and are not FDA-cleared for the indication.
Sources
- Faglia Diabetes Care 1996, PMID 8941460
- Margolis Diabetes Care 2013, PMID 23423696
- Kranke Cochrane Review 2015, PMID 26106870
- Scientific Reports meta-analysis, 2021
- Clinical Outcomes Systematic Review, PMC 2024
- Wagner-based meta-analysis, PMC 2024
- J Vasc Surg arterial insufficiency review, 2019
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- UHMS accredited facility directory, current 2026
Medical disclaimer
This page is medical journalism, not medical advice. Diabetic foot ulcer is a serious condition that can lead to limb loss. HBOT treats selected diabetic foot ulcers as an adjunct to standard wound care; it does not cure diabetes or guarantee healing. Talk to a wound care specialist or endocrinologist about treatment decisions. Do not delay standard care while pursuing HBOT.